You just read:

Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference

News provided by

Quark Pharmaceuticals, Inc.

Oct 09, 2017, 08:00 ET